Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 • 11,070 citations

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

2008 • 3,395 citations

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

2008 • 3,101 citations

The molecular biology of head and neck cancer

2010 • 2,364 citations

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

2004 • 1,709 citations

Cetuximab in the treatment of colorectal cancer.

2004 • 1,501 citations

Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma

2003 • 1,289 citations

Potent antibody therapeutics by design

2006 • 1,076 citations

Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study

2005 • 879 citations

Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

2001 • 858 citations

Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.

1993 • 837 citations

Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers

2013 • 540 citations

Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

2009 • 492 citations

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

2014 • 424 citations

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

2013 • 416 citations

Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.

2001 • 299 citations

Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients

2013 • 291 citations

Monoclonal antibodies for cancer immunotherapy

2009 • 291 citations

Assembly and Initial Characterization of a Panel of 85 Genomically Validated Cell Lines from Diverse Head and Neck Tumor Sites

2011 • 256 citations

Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines.

1989 • 254 citations

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

2009 • 216 citations

Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial

2015 • 164 citations

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

2009 • 157 citations

Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial

2015 • 153 citations

Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity

2011 • 149 citations

Preclinical Comparison of Near-Infrared-Labeled Cetuximab and Panitumumab for Optical Imaging of Head and Neck Squamous Cell Carcinoma

2013 • 99 citations

Immune Activation by Epidermal Growth Factor Receptor–Specific Monoclonal Antibody Therapy for Head and Neck Cancer

2007 • 92 citations

IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab

2010 • 75 citations

STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients

2015 • 66 citations

Exploring biomarkers in head and neck cancer

2012 • 64 citations

Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients

2015 • 47 citations

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab

2008 • 46 citations

Novel Immunogenic HLA-A*0201-restricted Epidermal Growth Factor Receptor-specific T-cell Epitope in Head and Neck Cancer Patients

2009 • 31 citations